

Origimed finishes series B round for oncology precision medicine

04 January 2019 | News

Origimed is devoted to bringing more clinical options, knowledge and precision oncology experience to the Chinese clinical cancer community and increasing the influence of Chinese cancer patients' data on the world precision oncology partners and collaborators



Origimed Co., Ltd., has formally announced the completion of its Series B financing. This round of financing is led by Grand Flight Investment. The pre-A financing investor Wedo Capital continued to invest.

The current round of financing aims at funding the next phase of R&D and expanding the influence of the oncology precision medicine data platform in China.

Since its founding in 2016, Origimed has completed 4 rounds of financing which including an Angel Round led by IDG Capital, Pre-A Round led by Wedo Capital, A Round led by Star VC and B Round led by Grand Flight Investment.

Established in May 2016, Origimed is a medical science and technology transforming company devoted to providing comprehensive molecular diagnostic information for cancer patients by leveraging next-generation sequencing technology.

It also provides molecular pathology and genomics services for biopharma partners to accelerate new biomarker-driven drug launching. Origimed has completed 10 million pan-cancer panel tests in a large variety of tumor types in China, supporting clinical decisions, driving innovation in cancer precision medicine and clinical treatment in China.

Looking forward, Origimed is devoted to bringing more clinical options, knowledge and precision oncology experience to the Chinese clinical cancer community and increasing the influence of Chinese cancer patients' data on the world precision oncology partners and collaborators.